Large-scale studies will be required to identify the complexity of genetic variations that affect how patients respond to a given drug and whether they will have side effects, according to researchers at Vanderbilt University Medical Center.

Dan Roden, MD, Senior Vice President for Personalized Medicine at Vanderbilt University Medical Center, received the Oscar B. Hunter Career Award in Therapeutics last week at the virtual annual meeting of the American Society for Clinical Pharmacology and Therapeutics.

With the aid of a $75 million, five-year grant renewal, the Electronic Medical Records and Genomics Network (eMERGE) will venture beyond its current focus on monogenic disease to scoring research participants’ relative risk for complex heritable diseases such as cardiovascular disease, chronic kidney disease and type 2 diabetes.

Vanderbilt University Medical Center investigators have used high-throughput robotic technology to rapidly study and classify variations in a gene linked to heart rhythm disorders and cardiac conditions.

A new clinic opening at Vanderbilt University Medical Center will help doctors and patients choose the best drugs for their medical conditions based on the patients’ unique genetic makeup.

Dan Roden, MD, and Daniel Munoz, have been named interim directors of the Division of Cardiovascular Medicine at Vanderbilt University Medical Center.